5090792026-04-012026-06-305090792026-04-012026-06-30in-capmkt:OtherExpenses1Memberiso4217:INRxbrli:pureiso4217:INRxbrli:shares509079GUFICBIONOTLISTEDINE742B01025Gufic Biosciences LimitedMain BoardEquity2026-04-012027-03-312026-08-142026-08-10INRLakhsQuarterlyFirst quarterSingle segmentThe Company's business activity falls within a single operating segment i.e. Pharmaceuticals2026-08-1417:00:002026-08-1418:10:00Not applicablefalsefalseThe Company has not defaulted in payment of interest/ instalment obligations on loans from Banks and Financial Institutions. Further, the Company does not have any outstanding debt securities (including Commercial Paper), Medium Term Notes (MTNs), Foreign Currency Convertible Bonds (FCCBs), External Commercial Borrowings (ECBs), etc. 2026-04-012026-06-30UnauditedStandalone2608180000457500026127550001061420000140308000-5173100041804900093184000770610005728440002311135000301620000030162000060800000162150007701500002246050000000224605000022460500010028300012.242.24002.242.240001. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder. <br /> <br /> 2. The above results for the quarter ended June 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 14, 2026. The Statutory Auditors have carried out limited review of the results for quarter ended June 30, 2026. <br /> <br /> 3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals. <br /> <br /> 4. The equity shares and basic/diluted earnings per share has been presented in accordance with Ind AS - 33-Earning per share. <br /> <br /> 5. The figures for the quarter ended March 31, 2026 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to -date figures up to the third quarter ended December 31, 2025 which were subjected to limited review. <br /> <br /> 6. Previous year/quarters figures have been regrouped/reclassified, wherever necessary.Other Expenses572844000000